theresa
w
guilbert
jame
e
gern
robert
f
lemansk
jr
bronchiol
increas
substanti
rsv
etiolog
episod
howev
bronchiol
sever
form
rsv
infect
occur
minor
children
age
year
children
infect
viru
age
year
nearli
children
age
month
born
close
onset
viral
season
prone
develop
lower
respiratori
tract
symptom
like
due
development
compon
eg
airway
lung
parenchyma
andor
immunolog
matur
furthermor
infant
birth
month
winter
viru
peak
predict
increas
likelihood
develop
childhood
asthma
addit
risk
factor
bronchiol
includ
antivir
immun
respons
innat
adapt
gender
lung
size
passiv
smoke
exposur
sever
larg
longterm
prospect
studi
children
demonstr
rsv
bronchiol
signific
independ
risk
factor
recurr
wheez
asthma
least
within
first
decad
life
longitudin
populationbas
cohort
studi
demonstr
associ
rsv
lri
frequent
episod
infrequ
wheez
episod
decreas
markedli
age
becom
nonsignific
age
year
decreas
frequenc
wheez
increas
age
document
rsv
infect
observ
investig
well
data
suggest
although
rsv
infect
contribut
substanti
risk
recurr
wheez
asthma
earli
childhood
cofactor
eg
genet
environment
development
also
contribut
initi
express
asthma
modif
phenotyp
time
although
bronchiol
diagnosi
infanc
associ
approxim
increas
risk
earli
childhood
asthma
risk
differ
season
bronchiol
bronchiol
occur
hrvpredomin
month
spring
fall
associ
estim
increas
risk
earli
childhood
asthma
compar
rsvpredomin
winter
month
howev
proport
associ
asthma
winter
season
bronchiol
greater
hrvpredomin
month
higher
rate
bronchiol
rsv
season
anoth
studi
kuesel
cowork
demonstr
although
rsv
associ
sever
lri
requir
hospit
hrv
associ
three
time
number
wheez
nonwheez
lri
infanc
find
support
concept
hrv
also
import
caus
bronchiol
appear
indic
risk
develop
asthma
respiratori
infect
caus
wheez
ill
children
age
also
may
influenc
develop
sever
asthma
respiratori
tract
infect
caus
virus
chlamydia
mycoplasma
implic
pathogenesi
asthma
respiratori
pathogen
virus
demonstr
epidemiolog
associ
asthma
sever
way
figur
first
certain
virus
associ
infantil
wheez
implic
potenti
respons
incept
asthmat
phenotyp
second
children
establish
asthma
viral
upper
respiratori
tract
infect
uri
play
signific
role
produc
acut
exacerb
may
result
healthcar
util
furthermor
children
develop
sever
viral
respiratori
infect
first
year
life
like
asthma
later
childhood
sever
host
factor
includ
respiratori
allergi
virusinduc
interferon
respons
modifi
risk
virusinduc
wheez
treatment
virusinduc
wheez
exacerb
asthma
challeng
studi
evalu
current
treatment
strategi
review
infect
microbi
agent
attent
focus
chlamydophila
mycoplasma
potenti
contributor
exacerb
sever
chronic
asthma
final
colon
upper
airway
infanc
common
bacteri
pathogen
associ
increas
risk
subsequ
asthma
review
variou
associ
pertain
pathogenesi
treatment
childhood
asthma
one
common
viral
ill
lead
lower
respiratori
tract
infect
lri
wheez
infanc
respiratori
syncyti
viru
rsv
use
multipl
viru
detect
method
includ
polymeras
chain
reaction
pcr
jartti
colleagu
investig
etiolog
wheez
ill
hospit
children
infant
viru
detect
rsv
picornaviru
human
rhinoviru
hrv
enteroviru
human
hmpv
older
children
respiratori
picornavirus
domin
children
age
year
children
age
year
rate
hospit
infant
section
f
asthma
chapter
ratori
allergi
asthma
contrast
find
upper
airway
prospect
studi
cold
coupl
consist
one
asthmat
one
normal
individu
demonstr
cold
caus
greater
durat
sever
lower
respiratori
symptom
subject
asthma
find
suggest
asthma
associ
fundament
differ
lower
airway
necessarili
upper
airway
manifest
respiratori
viral
infect
addit
provok
asthma
hrv
infect
increas
lower
airway
obstruct
individu
chronic
airway
diseas
eg
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
thu
common
cold
virus
produc
rel
mild
ill
peopl
caus
sever
pulmonari
problem
select
individu
hygien
hypothesi
postul
viral
bacteri
infect
might
actual
protect
subsequ
develop
allergi
asthma
david
strachan
first
note
risk
develop
allergi
asthma
invers
relat
number
children
famili
observ
duplic
number
subsequ
studi
find
led
specul
infecti
diseas
like
transmit
larg
famili
daycar
center
could
modul
develop
immun
system
manner
reduc
chanc
develop
allergi
hypothesi
impli
immun
system
skew
toward
helper
cell
type
like
respons
pattern
birth
support
concept
experiment
evid
show
interferon
respons
depress
birth
like
depress
children
develop
recurr
wheez
accord
hypothesi
viral
infect
would
provid
stimulu
develop
activ
immun
respons
result
repetit
stimul
would
chang
polar
th
system
away
overexpress
thu
reduc
risk
develop
allergi
figur
howev
evid
viral
infect
respiratori
tract
protect
either
allergi
asthma
fact
previous
describ
bronchiol
pneumonia
infanc
indic
increas
risk
subsequ
asthma
led
specul
site
infect
might
also
import
factor
relat
asthma
risk
possibl
gastrointestin
infect
protect
epidemiolog
biolog
factor
influenc
risk
allerg
sensit
andor
asthma
includ
earli
exposur
pet
farm
host
factor
atopi
decreas
lung
function
infanc
may
also
potenti
risk
recurr
wheez
andor
asthma
premorbid
measur
lung
function
indic
children
reduc
level
lung
function
infanc
appear
increas
risk
develop
chronic
lower
respiratori
tract
sequela
viral
infect
obstruct
pattern
lung
function
adulthood
whether
reduc
lung
function
alon
respons
develop
present
unknown
children
earli
atopi
less
year
like
diagnos
current
wheez
asthma
lri
rsv
hrv
infanc
thu
viral
infect
may
interact
atopi
reduc
lung
function
infanc
promot
later
asthma
relationship
viral
infect
exacerb
asthma
clarifi
advent
sensit
diagnost
test
base
polymeras
chain
reaction
pcr
virus
difficult
cultur
hrv
hmpv
bocavirus
advent
sensit
diagnost
tool
inform
link
common
cold
infect
exacerb
asthma
come
number
sourc
prospect
studi
subject
asthma
demonstr
exacerb
wheez
asthma
children
caus
viral
infect
although
mani
respiratori
virus
provok
acut
asthma
symptom
hrv
often
detect
especi
spring
fall
hrv
season
fact
spring
fall
peak
hospit
asthma
close
coincid
pattern
hrv
isol
within
commun
hrv
infect
frequent
detect
children
older
year
present
emerg
depart
acut
wheez
children
hospit
acut
asthma
newli
discov
hrv
speci
hrvc
associ
asthma
exacerb
children
fall
winter
influenza
rsv
somewhat
like
trigger
acut
asthma
symptom
winter
appear
account
smaller
fraction
total
asthma
flare
virus
less
frequent
associ
exacerb
asthma
includ
bocaviru
metapneumonviru
coronavirus
togeth
studi
provid
evid
strong
relationship
viral
infect
particularli
hrv
acut
exacerb
asthma
interest
individu
asthma
necessarili
cold
neither
sever
durat
virusinduc
upper
respiratori
symptom
enhanc
respi
infect
influenc
pathophysiolog
asthma
number
way
first
may
involv
incept
asthmat
phenotyp
within
first
decad
life
second
asthma
clinic
recogn
viral
infect
may
caus
diseas
exacerb
patient
intermitt
persist
phenotyp
third
asthma
goe
remiss
possibl
certain
infect
may
contribut
diseas
relaps
fourth
infect
may
contribut
diseas
chronic
andor
sever
time
fifth
infect
base
type
frequenc
target
organ
involv
andor
time
may
actual
prevent
develop
allerg
sensit
perhap
asthma
well
final
allerg
sensit
allergen
exposur
may
act
import
cofactor
clinic
express
asthmat
respons
variou
infect
bronchoscopi
pcr
c
pneumoniaeposit
sampl
patient
asthma
cultur
blood
sampl
reveal
significantli
higher
proport
asthma
subject
posit
chlamydia
compar
match
nonrespiratori
control
subject
interest
specul
chronic
chlamydophila
infect
promot
ongo
airway
inflamm
increas
suscept
exacerb
stimuli
virus
allergen
thu
far
comprehens
evalu
role
chlamydophila
mycoplasm
infect
chronic
asthma
recent
report
martin
colleagu
group
investig
evalu
adult
patient
chronic
asthma
percent
predict
forc
expiratori
volum
second
fev
control
infect
mycoplasma
c
pneumonia
virus
bronchoalveolar
lavag
cell
count
differenti
well
tissu
morphometri
also
evalu
asthmat
patient
posit
pcr
pneumonia
n
c
pneumonia
n
mainli
found
lavag
fluid
biopsi
sampl
control
subject
posit
pcr
mycoplasma
distinguish
featur
patient
posit
neg
pcr
result
significantli
greater
number
tissu
mast
cell
group
patient
posit
pcr
cultur
organ
neg
patient
serolog
confirm
correl
poorli
pcr
result
anoth
studi
biscardi
colleagu
children
age
year
previou
histori
asthma
hospit
sever
asthma
exacerb
test
acut
infect
due
pneumonia
c
pneumonia
determin
posit
result
serolog
test
nasopharyng
aspir
pcr
also
perform
acut
pneumonia
infect
posit
serolog
found
c
pneumonia
infect
found
patient
current
exacerb
patient
experienc
first
asthma
attack
acut
pneumonia
infect
proven
patient
c
pneumonia
children
experienc
first
asthma
attack
infect
pneumonia
c
pneumonia
asthma
recurr
without
infect
asthma
recurr
similar
previou
studi
serolog
confirm
correl
poorli
pcr
result
chronic
chlamydophila
infect
may
possibl
promot
ongo
airway
inflamm
increas
suscept
exacerb
stimuli
virus
allergen
substanti
contribut
c
pneumonia
asthma
result
pharmacolog
intervent
trial
noteworthi
one
studi
roxithromycin
administ
week
group
adult
asthmat
patient
serolog
evid
concurr
infect
c
pneumonia
small
signific
improv
observ
morn
even
peak
expiratori
flow
rate
howev
improv
sustain
sever
month
discontinu
therapi
control
group
includ
pediatr
trial
children
age
year
acut
episod
wheez
agematch
healthi
children
studi
sera
specif
antibodi
level
nasopharyng
aspir
pcr
detect
pneumonia
c
pneumonia
obtain
admiss
week
children
wheez
receiv
standard
therapi
inhal
corticosteroid
bronchodil
day
receiv
cours
clarithromycin
irrespect
serolog
pcr
result
judgement
pediatrician
charg
followup
period
among
children
evid
acut
pneumonia
andor
c
pneumonia
infect
significantli
nonantibiotictr
subject
show
recurr
wheez
convers
none
lifestyl
alter
bacteri
flora
gut
increas
use
antibiot
furthermor
exposur
high
level
endotoxin
home
occur
farmhous
associ
reduc
rate
allergi
enhanc
number
interferonproduc
cell
peripher
blood
collect
studi
suggest
exposur
microb
may
greater
effect
actual
infect
immun
develop
risk
atopi
asthma
epidemiolog
biolog
factor
consid
influenc
develop
allerg
sensit
andor
asthma
review
detail
chapter
propos
chronic
viral
bacteri
infect
colon
pathogen
bacteria
could
initi
chronic
lower
airway
inflamm
impair
mucociliari
clearanc
increas
mucu
product
ultim
asthma
organ
primarili
implic
process
includ
adenoviru
chlamydophila
pneumonia
mycoplasma
pneumonia
pneumonia
h
influenza
catarrhali
studi
chronic
mycobacteria
chlamydophila
infect
asthma
children
yield
conflict
result
probabl
part
due
limit
current
diagnost
find
diagnost
test
upper
lower
airway
alway
concurr
diagnosi
infect
serolog
lead
inaccuraci
histor
first
potenti
associ
asthma
c
pneumonia
report
wheez
adult
asthmat
patient
found
serolog
evid
current
recent
infect
organ
schoolag
children
wheez
unexpectedli
high
preval
lowgrad
c
pneumonia
infect
nasal
aspir
report
detect
c
pneumonia
infect
pcr
serolog
secretori
iga
similar
symptomat
asymptomat
episod
vs
respect
children
report
multipl
episod
also
tend
remain
pcr
posit
c
pneumonia
suggest
chronic
infect
c
pneumoniaespecif
secretori
iga
antibodi
time
greater
subject
report
four
exacerb
studi
compar
report
one
studi
pediatr
patient
undergo
flexibl
fiberopt
latent
infect
persist
mani
year
sloven
studi
demonstr
children
steroidresist
asthma
detect
adenoviru
antigen
compar
control
adult
without
asthma
evid
adenovir
infect
report
high
individu
test
recent
studi
bisgaard
cowork
found
neonat
colon
hypopharyng
region
pneumonia
h
influenza
catarrhali
combin
organ
increas
risk
recurr
wheez
earli
life
diagnosi
asthma
age
year
although
preliminari
result
intrigu
addit
studi
need
establish
causal
specif
observ
asthma
pathogenesi
defin
immunoinflammatori
mechan
contribut
associ
adult
pediatr
patient
natur
associ
asthma
sinus
children
adult
subject
debat
mani
year
much
difficulti
defin
relationship
result
uncertainti
make
clinic
diagnosi
sinus
sign
symptom
sinus
children
overlap
mani
common
childhood
respiratori
disord
includ
common
cold
allerg
rhiniti
asthma
review
chapter
untreat
sinu
diseas
may
contribut
unstabl
asthma
control
patient
bacteri
infect
clearli
involv
acut
chronic
sinu
diseas
mechan
microb
may
promot
ahr
lower
airway
great
interest
relationship
cover
depth
elsewher
text
therefor
review
chapter
sever
mechan
propos
explain
respiratori
virus
caus
wheez
ill
exacerb
asthma
box
first
viral
infect
damag
airway
epitheli
cell
caus
airway
edema
leakag
serum
protein
airway
effect
togeth
shed
infect
cell
airway
lead
obstruct
wheez
addit
virusinduc
immun
respons
necessari
clear
clarithromycintr
patient
show
new
episod
wheez
date
data
difficult
interpret
limit
number
studi
difficulti
erad
chlamydia
mycoplasma
infect
fact
mani
macrolid
antibiot
antiinflammatori
effect
addit
serv
antimicrobi
c
pneumonia
infect
inde
contribut
asthma
chronic
diseas
sever
instabl
mechan
may
contribut
effect
regard
investig
propos
develop
c
pneumoniaespecif
immunoglobulin
e
ige
antibodi
caus
releas
mediat
lead
bronchospasm
airway
inflamm
airway
reactiv
unless
organ
erad
antibiot
therapi
antigen
stimul
lead
specif
ige
product
would
persist
therebi
explain
protract
cours
asthma
patient
unrespons
aggress
use
bronchodil
steroid
addit
indic
previous
major
c
pneumonia
antigen
heat
shock
protein
protein
implic
induct
deleteri
immun
respons
human
chlamydi
infect
found
coloc
infiltr
macrophag
atheromat
lesion
recent
found
potent
induc
macrophag
inflammatori
respons
mediat
innat
immun
receptor
complex
tolllik
receptor
latter
find
suggest
chronic
asymptomat
chlamydi
infect
may
perpetu
ongo
airway
inflammatori
respons
innat
adapt
immun
respons
briefli
introduc
previous
pneumonia
also
associ
acut
chronic
asthma
variou
investig
abl
uniformli
establish
potenti
mycoplasm
infect
induc
acut
exacerb
asthma
although
report
infect
children
wheez
other
abl
substanti
observ
inde
popul
children
evalu
rel
contribut
mycoplasm
chlamydi
infect
acut
exacerb
viral
etiolog
far
frequent
implic
possibl
data
may
alter
futur
sensit
specif
serolog
diagnost
test
becom
avail
andor
cultur
techniqu
improv
contrast
effect
pathogen
mycoplasma
speci
acut
asthma
exacerb
associ
microb
chronic
asthma
secur
establish
use
pcr
techniqu
bronchial
biopsi
specimen
mycoplasma
speci
detect
adult
asthmat
subject
control
case
report
chronic
asthma
begin
pneumonia
infect
suggest
infect
potenti
caus
agent
patient
regard
possibl
causal
mechan
mycoplasmainduc
airway
inflamm
investig
includ
increas
respons
inflammatori
neuropeptid
children
acut
pneumonia
elev
interleukin
il
ifn
ratio
compar
children
pneumococc
pneumonia
control
mice
experiment
infect
pneumonia
develop
airway
hyperrespons
ahr
associ
decreas
product
mrna
addit
asthmat
patient
pneumonia
infect
detect
pcr
elev
level
neurokinin
respond
treatment
macrolid
antibiot
one
addit
mechan
implic
pathogenesi
chronic
asthmat
symptom
latent
adenoviru
infect
latent
infect
occur
viru
incorpor
host
cell
dna
continu
period
express
viral
gene
respiratori
diseas
caus
adenovirus
follow
virusinduc
damag
airway
airway
edema
transud
serum
protein
respiratori
viral
infect
may
enhanc
underli
airway
inflamm
asthma
least
two
way
directli
infect
lower
airway
epitheli
cell
indirectli
infect
upper
airway
gener
system
immun
respons
characterist
featur
respiratori
viral
infect
abil
enhanc
airway
respons
normal
asthmat
individu
interact
respiratori
viral
infect
allerg
inflamm
tom
lower
airway
dysfunct
viru
attach
cell
surfac
receptor
initi
immun
respons
exampl
rsv
infect
activ
signal
pathway
airway
epitheli
cell
innat
immun
system
tolllik
apart
receptor
activ
develop
oxid
stress
viral
infect
activ
epitheli
cell
respons
viral
rna
bind
cell
surfac
receptor
tolllik
intracellular
protein
dsrnadepend
protein
kinas
retino
acidinduc
gene
activ
innat
antivir
immun
respons
pathway
viral
replic
stimul
product
nitric
oxid
activ
rnase
l
inhibit
protein
synthesi
within
infect
cell
addit
innat
antivir
respons
induc
chemokin
recruit
inflammatori
cell
airway
hrvinfect
epitheli
cell
secret
rant
protein
ip
induc
cell
chemotaxi
notabl
express
augment
asthma
exacerb
caus
hrv
virus
level
express
report
differenti
virusinduc
nonvirusinduc
asthma
exacerb
final
viral
respiratori
infect
induc
synthesi
mani
factor
regul
airway
alveolar
develop
remodel
includ
vascular
endotheli
growth
factor
vegf
nitric
oxid
fibroblast
growth
factor
fgf
singl
repeat
bout
virusinduc
overexpress
regul
lung
develop
remodel
affect
ultim
lung
structur
function
known
interest
regard
longterm
effect
lung
function
asthma
monocyt
macrophag
activ
virus
secret
proinflammatori
cytokin
tumor
necrosi
factor
tnf
anim
model
respiratori
viral
infect
lead
promin
expans
matur
dendrit
cell
lung
lung
dendrit
cell
strong
facil
activ
memori
cell
stimul
prolifer
increas
number
lung
dendrit
cell
creat
local
precursor
lung
surviv
past
resolut
diseas
rsv
infect
significantli
pulmonari
dendrit
cell
express
high
level
tolllik
receptor
secret
larg
amount
interferon
respons
viral
infect
acut
respiratori
viral
infect
often
accompani
neutrophilia
upper
lower
respiratori
secret
product
neutrophil
activ
like
involv
obstruct
airway
caus
lower
airway
symptom
importantli
evid
activ
neutrophil
releas
potent
secretagogu
elastas
upregul
goblet
cell
secret
mucu
addit
chang
level
nasal
secret
relat
respiratori
symptom
virusinduc
increas
ahr
cation
channel
express
leukocyt
airway
epitheli
cell
import
pathogen
control
concomit
cellular
inflamm
recent
studi
denling
cowork
demonstr
attenu
function
common
mild
moder
asthma
attenu
function
associ
reduc
recruit
neutrophil
airway
hrv
cold
increas
risk
acut
asthma
symptom
even
adjust
inhal
corticosteroid
treatment
thu
attenu
pore
activ
may
import
regul
virusinduc
neutrophilia
potenti
novel
biomark
loss
asthma
control
hrv
infect
viral
infect
could
also
contribut
airway
dysfunct
symptom
caus
influx
inflammatori
cell
advers
affect
lower
airway
physiolog
respiratori
virus
enhanc
airway
inflamm
directli
infect
lower
airway
tissu
possibl
infect
upper
airway
induc
system
immun
respons
potenti
lower
airway
inflamm
environment
factor
may
import
influenc
outcom
viral
infect
viral
infect
known
trigger
asthma
exert
synergist
effect
caus
acut
exacerb
allergi
strong
risk
factor
develop
asthma
virusinduc
wheez
episod
infanc
also
close
associ
virusinduc
exacerb
asthma
older
children
adult
asthma
exampl
effect
cold
asthma
may
amplifi
exposur
allergen
exposur
greater
level
air
pollut
mechan
underli
virusinduc
wheez
episod
asthma
discuss
follow
section
respiratori
virus
rsv
influenza
well
known
infect
lower
airway
caus
bronchiti
bronchiol
pneumonia
hrv
tradit
consid
upper
airway
pathogen
associ
common
cold
symptom
observ
hrv
replic
best
approxim
temperatur
upper
airway
fact
lower
airway
temperatur
directli
map
use
bronchoscop
equip
small
thermistor
quiet
breath
room
temperatur
airway
temperatur
conduc
hrv
replic
fourthgener
bronchi
exceed
peripheri
lung
moreov
hrv
appear
replic
equal
well
cultur
epitheli
cell
deriv
either
upper
lower
airway
epithelium
final
hrv
detect
lower
airway
cell
secret
sever
techniqu
experiment
inocul
titer
infecti
viru
lower
sputum
reach
exceed
found
nasal
secret
individu
addit
evid
experiment
infect
model
hrv
frequent
detect
infant
children
lower
respiratori
sign
symptom
includ
children
hospit
pneumonia
collect
find
suggest
respiratori
virus
includ
hrv
like
caus
wheez
ill
exacerb
asthma
mainli
infect
lower
airway
caus
amplifi
lower
airway
inflamm
respiratori
virus
replic
primarili
upper
lower
airway
epitheli
cell
figur
virusinduc
injuri
epithelium
disrupt
airway
physiolog
number
differ
pathway
box
exampl
epitheli
edema
slough
togeth
mucu
product
lead
airway
obstruct
wheez
result
epitheli
damag
also
increas
permeabl
mucos
layer
may
facilit
contact
irrit
allergen
immun
cell
leav
neural
element
expos
enhanc
viral
replic
less
differenti
basal
epitheli
cell
process
associ
viral
replic
trigger
innat
adapt
immun
respons
within
epitheli
cell
virus
hrv
infect
rel
cell
airway
may
primari
mechan
airway
sympaft
rsv
risk
factor
subsequ
asthma
evid
vitro
asthma
associ
impair
virusinduc
secret
interferon
airway
peripher
blood
cell
togeth
experiment
find
suggest
cellular
immun
respons
respiratori
virus
interferon
respons
particular
influenc
clinic
virolog
outcom
infect
impact
allerg
sensit
may
asthmat
airway
respons
viral
infect
gener
much
interest
research
interact
two
factor
appear
bidirect
dynam
atop
state
influenc
lower
airway
respons
viral
infect
viral
infect
influenc
develop
allergen
sensit
interact
occur
individu
expos
simultan
allergen
virus
atopi
risk
factor
develop
childhood
asthma
virusinduc
wheez
ill
defin
mechan
relationship
interest
mani
investig
group
also
suggest
atopi
could
signific
predispos
factor
develop
acut
bronchiol
rsv
epidem
although
found
children
like
persist
wheez
born
atop
parent
other
found
similarli
debat
whether
person
atopi
preval
bronchiol
despit
uncertainti
clear
children
wheez
earli
life
atop
featur
allerg
sensit
atop
dermat
either
blood
eosinophilia
allergenspecif
ige
highest
risk
subsequ
asthma
observ
led
develop
predict
indic
estim
risk
asthma
wheez
infanc
tabl
convinc
evid
implic
respiratori
allergi
risk
factor
wheez
common
cold
infect
later
lymphocyt
recruit
upper
lower
airway
earli
stage
viral
respiratori
infect
presum
cell
help
limit
extent
infect
clear
virusinfect
epitheli
cell
consist
report
sever
viral
lri
immunocompromis
patient
viru
inocul
b
cell
respons
infect
detect
gener
mucos
iga
day
follow
igm
final
igg
day
rapid
induct
specif
preform
neutral
igg
hrv
serv
prevent
limit
degre
reinfect
sever
studi
test
hypothesi
individu
variat
cellular
immun
respons
pattern
cytokin
product
relat
outcom
respiratori
infect
studi
children
high
risk
develop
asthma
base
parent
histori
reduc
mitogeninduc
product
cord
blood
mononuclear
cell
ex
vivo
associ
signific
increas
viral
respiratori
ill
infanc
airway
epitheli
cell
serv
host
viral
replic
help
initi
innat
immun
respons
infect
innat
adapt
immun
respons
viral
infect
promot
viral
clearanc
howev
may
augment
ongo
local
inflammatori
respons
well
evid
effect
antivir
respons
depend
factor
relat
host
development
genet
viru
strain
virul
environ
allergen
pollut
nutrit
indic
virus
enhanc
airway
hyperrespons
one
key
featur
asthma
clinic
studi
human
volunt
inocul
common
cold
virus
gener
shown
viral
infect
caus
mild
increas
airway
respons
time
peak
cold
symptom
chang
last
sever
week
heighten
sensit
inhal
irrit
well
greater
maximum
bronchoconstrict
respons
stimuli
observ
mechan
virusinduc
airway
respons
like
multifactori
contribut
factor
like
includ
impair
inactiv
tachykinin
viru
effect
nitric
oxid
product
virusinduc
chang
neural
control
airway
tachykinin
synthes
sensori
nerv
potent
bronchoconstrictor
vasodil
effect
potenti
caus
sever
airway
obstruct
airway
epitheli
cell
help
regul
tachykinin
level
product
enzym
neutral
endopeptidas
loss
enzym
activ
epithelium
damag
viral
infect
could
lead
airway
obstruct
nitric
oxid
regul
vascular
bronchial
tone
interfer
replic
virus
nitric
oxid
synthesi
enhanc
viral
infect
mani
potenti
effect
nitric
oxid
lower
airway
uncertain
whether
benefici
lower
airway
function
asthma
virus
also
affect
airway
tone
respons
enhanc
vagal
mediat
reflex
bronchoconstrict
potenti
mechan
effect
viru
interfer
function
muscarin
receptor
receptor
part
import
neg
feedback
loop
limit
releas
acetylcholin
vagal
nerv
end
receptor
damag
viral
infect
virusinduc
interferon
bronchoconstrict
enhanc
lead
increas
airway
obstruct
delin
pathway
may
lead
novel
treatment
virusinduc
asthma
symptom
refractori
standard
therapi
virusinduc
cough
wheez
lead
signific
morbid
particularli
difficult
treat
potenti
therapi
includ
use
bronchodil
antiinflammatori
agent
strategi
base
antivir
approach
either
prevent
treatment
acut
wheez
convent
therapi
virusinduc
wheez
young
children
commonli
includ
stepwis
addit
medic
typic
start
bronchodil
lower
respiratori
tract
symptom
becom
increasingli
sever
respiratori
distress
develop
oral
corticosteroid
often
ad
recent
clinic
trial
manag
wheez
episod
also
includ
use
highdos
inhal
corticosteroid
ic
prophylact
acut
intervent
leukotrien
receptor
antagonist
box
strategi
review
follow
section
efficaci
variou
therapeut
intervent
acut
symptom
wheez
tachypnea
retract
hypoxemia
childhood
studi
conduct
emerg
depart
risk
factor
develop
acut
wheez
episod
determin
individu
risk
factor
develop
wheez
includ
detect
respiratori
viru
commonli
hrv
posit
allergenspecif
ige
rast
presenc
eosinophil
inflamm
notabl
viral
infect
allerg
inflamm
synergist
enhanc
risk
wheez
furthermor
experiment
inocul
hrv
like
increas
airway
respons
allerg
individu
compar
nonallerg
individu
lastli
risk
hospit
among
virusinfect
individu
increas
patient
sensit
expos
respiratori
allergen
find
suggest
individu
respiratori
allergi
eosinophil
airway
inflamm
increas
risk
wheez
viru
concept
difficult
model
use
experimentallyinduc
cold
howev
allergen
administr
inocul
enhanc
symptom
cold
viral
infect
postul
interact
allerg
inflamm
lead
airway
dysfunct
sever
mechan
exampl
viral
infect
could
damag
barrier
function
airway
epithelium
lead
enhanc
absorpt
aeroallergen
across
airway
wall
enhanc
inflamm
addit
product
variou
cytokin
tumor
necrosi
factor
tnf
chemokin
leukotrien
adhes
molecul
may
upregul
cellular
recruit
cell
activ
ongo
inflammatori
respons
inform
deriv
anim
model
well
clinic
studi
natur
experiment
induc
viral
infect
differ
indic
bold
origin
asthma
predict
index
api
base
data
tucson
children
respiratori
studi
posit
predict
valu
activ
asthma
age
year
convers
children
neg
api
result
activ
asthma
age
year
prevent
earli
asthma
kid
trial
modifi
publish
api
includ
allerg
sensit
aeroallergen
food
use
place
mddiagnos
allerg
rhiniti
difficult
diagnos
young
children
expect
modifi
index
would
similar
posit
predict
valu
origin
api
asthma
modifi
index
sinc
adopt
nation
asthma
educ
prevent
program
naepp
guidelin
identifi
children
high
risk
develop
asthma
may
benefit
asthma
control
therapi
guilbert
et
al
anoth
controversi
question
whether
corticosteroid
treatment
prevent
respiratori
sequela
bronchiol
sever
placebocontrol
trial
address
question
whether
corticosteroid
treatment
influenc
degre
respiratori
sequela
bronchiol
review
major
trial
show
longterm
effect
followup
time
month
year
postbronchiolit
wheez
develop
variou
wheez
phenotyp
transient
persist
late
onset
subsequ
diagnosi
asthma
trial
show
benefit
posit
effect
observ
mainli
shorter
time
interv
infect
one
studi
conclud
greatest
benefit
like
seen
atop
children
similar
studi
preschool
children
recurr
viralinduc
wheez
demonstr
atop
children
show
respons
inhal
corticosteroid
ic
addit
new
data
infant
wheez
hrv
less
like
develop
recurr
wheez
system
corticosteroid
therapi
initi
acut
infect
find
confirm
suggest
distinct
pathogenesi
therapeut
approach
infant
diagnos
hrv
wheez
ill
numer
studi
undertaken
assess
role
corticosteroid
therapi
acut
episod
asthma
children
adult
recent
metaanalysi
six
trial
involv
subject
assess
benefit
system
corticosteroid
treatment
asthmat
patient
discharg
acut
care
set
assess
treatment
acut
asthmat
exacerb
short
cours
corticosteroid
follow
assess
asthma
exacerb
significantli
reduc
number
relaps
addit
care
hospit
use
shortact
agonist
without
appar
increas
sideeffect
intramuscular
oral
corticosteroid
effect
reflect
inform
recent
nation
heart
lung
blood
institut
guidelin
diagnosi
manag
asthma
recommend
addit
corticosteroid
asthma
exacerb
unrespons
bronchodil
guidelin
suggest
introduct
oral
prednison
prednisolon
short
cours
may
reduc
durat
exacerb
prevent
hospit
howev
pediatr
studi
examin
whether
system
corticosteroid
reduc
sever
exacerb
children
bronchospasm
exclus
viral
infect
brunett
colleagu
explor
role
earli
intervent
oral
corticosteroid
therapi
children
age
year
mean
age
month
asthma
typic
provok
viral
uri
first
year
studi
acut
exacerb
treat
oral
bronchodil
initi
addit
prednison
sever
attack
second
year
oral
prednison
administ
first
sign
uri
group
patient
whose
parent
caretak
unblind
treatment
intervent
group
receiv
prednison
second
year
experienc
fewer
attack
reduct
number
wheez
day
decreas
emerg
depart
visit
decreas
hospit
administr
prednison
first
sign
uri
occur
result
bronchiol
controversi
variat
studi
design
inabl
rapidli
conveni
measur
pulmonari
physiolog
variabl
confound
result
inclus
children
histori
multipl
wheez
episod
ie
asthmat
phenotyp
choic
outcom
measur
evalu
cochran
metaanalysi
subject
bronchodil
found
gener
modest
shortterm
improv
clinic
featur
mild
moder
sever
bronchiol
differ
rate
durat
hospit
note
howev
given
high
cost
uncertain
benefit
therapi
author
conclud
bronchodil
could
recommend
routin
manag
firsttim
wheezer
similarli
recent
american
academi
pediatr
aap
bronchiol
guidelin
suggest
mani
children
bronchiol
show
respons
bronchodil
howev
care
monitor
trial
medic
option
inhal
bronchodil
could
continu
document
posit
clinic
respons
trial
use
object
mean
evalu
efficaci
therapi
either
oral
parenter
corticosteroid
review
metaanalysi
studi
sought
evalu
form
intervent
metaanalysi
studi
involv
therapi
either
oral
parenter
corticosteroid
conclud
approach
demonstr
pool
decreas
length
stay
day
howev
decreas
statist
signific
review
conclud
benefit
found
either
lo
length
stay
clinic
score
infant
young
children
treat
system
glucocorticoid
compar
placebo
two
addit
studi
evalu
inhal
corticosteroid
bronchiol
show
benefit
cours
acut
diseas
thu
aap
bronchiol
guidelin
recommend
corticosteroid
medic
use
routin
manag
bronchiol
safeti
highdos
inhal
corticosteroid
infant
still
clear
appar
benefit
demonstr
major
case
support
treatment
remain
standard
care
infant
bronchiol
inhal
corticosteroid
ic
treatment
respiratori
syncyti
viru
bronchiol
significantli
decreas
develop
chronic
lower
airway
symptomatolog
chronic
treatment
ic
reduc
frequenc
sever
intermitt
virusinduc
wheez
episod
children
multitrigg
wheez
complet
prevent
occurr
convers
nonatop
children
wheez
viral
infect
demonstr
ic
given
either
prophylact
acut
intervent
effect
reduc
sever
frequenc
virusinduc
wheez
episod
treatment
virusinduc
asthma
exacerb
oral
corticosteroid
significantli
improv
number
outcom
measur
overal
compar
efficaci
safeti
treatment
similar
episod
either
highdos
ic
leukotrien
modifi
warrant
studi
steroidand
noncorticosteroidtr
group
connett
lenney
compar
efficaci
two
dose
budesonid
mg
twice
daili
via
mdi
spacer
devic
initi
onset
upper
respiratori
tract
symptom
preschoolag
children
recurr
wheez
uri
therapi
continu
day
patient
asymptomat
hour
budesonid
therapi
associ
decreas
symptom
score
first
week
infect
doubleblind
placebocontrol
crossov
studi
svedmyr
colleagu
involv
administr
budesonid
mg
time
daili
day
time
daili
day
twice
daili
day
via
mdi
spacer
placebo
children
year
age
histori
uriassoci
deterior
asthma
although
budesonid
therapi
signific
impact
symptom
score
associ
significantli
higher
peak
expiratori
flow
rate
emerg
departmentbas
studi
volovitz
colleagu
compar
effect
inhal
budesonid
oral
prednisolon
children
age
year
acut
asthma
exacerb
patient
receiv
either
budesonid
mg
turbuhal
mgkg
oral
prednisolon
emerg
depart
follow
taper
dose
medic
next
day
treatment
group
similar
rate
improv
emerg
depart
term
symptom
score
peak
expiratori
flow
howev
next
week
budesonidetr
group
rapid
improv
asthma
symptom
serum
cortisol
level
respons
corticotropin
significantli
decreas
prednisolonetr
group
end
week
therapi
compar
budesonidetr
group
return
normal
rang
week
later
studi
suggest
highdos
therapi
potent
ic
may
effect
oral
prednisolon
avoid
hypothalamicpituitaryadren
axi
suppress
anoth
studi
compar
effect
highdos
icss
oral
corticosteroid
children
seen
emerg
depart
sever
acut
asthma
mean
fev
predict
present
found
oral
corticosteroid
superior
term
improv
lung
function
hospit
rate
howev
patient
clearli
middl
sever
exacerb
icss
use
earli
cours
ill
anoth
recent
studi
nonatop
preschool
children
moderatetosever
virusinduc
wheez
demonstr
reduct
use
rescu
oral
corticosteroid
wheez
episod
highdos
fluticason
use
intermitt
onset
ill
compar
placebo
suggest
potenti
benefit
inhal
corticosteroid
use
nonatop
children
recurr
wheez
howev
author
recommend
studi
done
treatment
strategi
adopt
small
statist
signific
decreas
height
growth
observ
summari
icss
appear
improv
asthma
symptom
administ
acut
exacerb
asthma
although
studi
provid
use
inform
limit
small
number
patient
delin
featur
predict
patient
would
expect
respond
given
therapi
addit
ideal
drug
dosag
deliveri
system
durat
therapi
remain
unclear
improv
deliveri
potent
drug
lower
airway
may
associ
favor
clinic
respons
cysteinyl
leukotrien
identifi
import
mediat
complex
pathophysiolog
asthma
leukotrien
associ
greater
overal
prednison
use
although
studi
suggest
earli
intervent
oral
corticosteroid
potenti
significantli
affect
morbid
associ
acut
virusinduc
asthma
episod
unblind
studi
design
make
result
less
convinc
tal
colleagu
conduct
emerg
departmentbas
doubleblind
placebocontrol
trial
administr
singl
dose
methylprednisolon
intramuscularli
demonstr
statist
signific
decreas
hospit
rate
methylprednisolon
group
vs
control
group
p
effect
pronounc
group
less
month
old
methylprednisolon
group
vs
control
group
p
taken
togeth
result
two
studi
suggest
earli
corticosteroid
therapi
ideal
start
home
impact
progress
asthma
episod
decreas
rate
hospit
asthma
convers
recent
studi
compar
oral
prednisolon
placebo
hospit
preschool
children
virusinduc
wheez
demonstr
benefit
length
hospit
symptom
score
albuterol
use
studi
suggest
nonatop
preschool
children
physiciandiagnos
hayfev
sever
wheez
episod
sever
enough
warrant
evalu
hospit
set
may
respond
corticosteroid
howev
system
corticosteroid
given
initi
evalu
hospit
set
exacerb
alreadi
well
underway
addit
one
third
children
prior
histori
wheez
young
children
experi
frequent
exacerb
asthma
may
receiv
sever
short
cours
system
corticosteroid
viral
season
potenti
toxic
repeat
cours
oral
corticosteroid
signific
clinic
concern
individu
cours
oral
corticosteroid
may
associ
behavior
sideeffect
addit
dolan
colleagu
report
children
receiv
four
short
cours
oral
corticosteroid
past
year
impair
respons
insulininduc
hypoglycemia
potenti
toxic
repeat
cours
oral
corticosteroid
signific
clinic
concern
like
influenc
behavior
primari
care
physician
face
young
children
wheez
uri
symptom
due
concern
sideeffect
repeat
dose
oral
corticosteroid
efficaci
ic
intervent
exacerb
evalu
sever
studi
first
wilson
silverman
examin
use
beclomethason
dipropion
mg
time
daili
day
administ
via
metereddos
inhal
mdi
first
sign
asthma
episod
children
year
age
although
fail
alter
need
addit
therapi
ic
therapi
associ
improv
asthma
symptom
first
week
episod
daugbjerg
colleagu
conduct
doubleblind
placebocontrol
trial
compar
effect
inhal
bronchodil
alon
combin
either
highdos
ic
budesonid
nebul
mg
everi
hour
discharg
system
corticosteroid
prednisolon
children
younger
month
admit
hospit
acut
wheez
result
demonstr
earlier
discharg
hospit
inhal
system
corticosteroidtr
group
well
significantli
acceler
rate
clinic
improv
budesonidetr
group
compar
oral
corticotori
tract
infect
asthma
symptom
minimum
day
emerg
depart
visit
reduc
visit
healthcar
practition
reduc
time
preschoolschool
parent
time
work
reduc
children
took
montelukast
median
day
ic
ltra
continu
treatment
regimen
demonstr
efficaci
preschool
children
comparison
conduct
suffici
rigor
order
better
clarifi
treatment
would
best
suit
individu
children
base
variou
phenotyp
genotyp
characterist
younger
children
year
age
mild
asthma
recurr
wheez
one
comparison
trial
continu
treatment
publish
studi
effect
ic
oncedaili
budesonid
inhal
suspens
mg
compar
ltra
oncedaili
oral
montelukast
mg
signific
betweengroup
differ
observ
primari
outcom
time
first
addit
asthma
medic
week
howev
secondari
outcom
time
first
addit
asthma
medic
longer
exacerb
rate
lower
period
week
budesonid
versu
montelukast
time
first
sever
exacerb
requir
oral
corticosteroid
similar
group
studi
signific
limit
children
complet
studi
one
third
children
adher
rate
less
addit
signific
portion
children
year
age
analys
stratifi
age
make
difficult
extrapol
conclus
toddler
wheez
age
group
final
studi
stratifi
atop
statu
recent
trial
acut
intervent
manag
strategi
aim
examin
effect
episod
use
highdos
inhal
corticosteroid
leukotrien
receptor
antagonist
placebo
respiratori
tract
ill
preschool
children
moderatetosever
intermitt
wheez
intermitt
budesonid
montelukast
modestli
improv
symptom
score
respiratori
tract
ill
improv
episodefre
day
efd
decreas
oral
corticosteroid
use
children
posit
asthma
predict
indic
requir
oral
corticosteroid
wheez
past
year
demonstr
benefit
influenza
vaccin
use
prevent
strategi
reduc
virusinduc
exacerb
asthma
winter
rsv
hrv
frequent
associ
wheez
ill
vaccin
avail
consid
well
strain
hrv
standard
vaccin
techniqu
technic
feasibl
viru
although
limit
high
cost
treatment
highrisk
group
passiv
prophylaxi
neutral
antibodi
rsv
reduc
influenc
sever
respiratori
diseas
encourag
small
casecontrol
studi
prematur
infant
treat
rsv
immun
globulin
report
better
lung
function
less
atopi
asthma
treat
group
year
later
addit
european
casecontrol
studi
infant
treat
palivizumab
lower
rate
recurr
wheez
compar
untreat
control
although
interpret
studi
limit
lack
random
find
provid
reason
optim
addit
prevent
studi
sever
antivir
agent
develop
number
antihrv
compound
detect
blood
urin
nasal
secret
sputum
bronchoalveolar
lavag
fluid
patient
chronic
asthma
addit
leukotrien
releas
acut
asthma
episod
volovitz
colleagu
demonstr
elev
level
leukotrien
c
ltc
nasopharyng
secret
infant
acut
bronchiol
rsv
compar
children
upper
respiratori
ill
alon
anoth
studi
van
schaik
colleagu
also
examin
leukotrien
level
nasopharyng
sampl
infant
young
children
uri
without
wheez
bronchiol
firsttim
wheezer
acut
episod
wheez
children
prior
wheez
episod
investig
found
elev
level
leukotrien
nasopharyng
sampl
firsttim
recurr
viral
wheezer
compar
children
nonwheez
uri
final
bronchoalveolar
lavag
sampl
obtain
young
children
median
age
month
recurr
wheez
contain
increas
number
epitheli
inflammatori
cell
also
increas
level
cyclooxygenas
lipoxygenas
pathway
mediat
interestingli
level
cell
mediat
unaffect
concurr
treatment
icss
studi
vitro
anim
model
also
suggest
leukotrien
contribut
virusinduc
wheez
asthma
exampl
rsv
induc
activ
bronchial
epitheli
cell
line
rat
model
treatment
leukotrien
antagonist
reduc
rsvinduc
airway
edema
rat
effect
leukotrien
receptor
antagonist
ltra
modul
virusinduc
wheez
evalu
clinic
studi
initi
pilot
studi
demonstr
treatment
cours
montelukast
significantli
reduc
lower
respiratori
tract
symptom
infant
hospit
rsv
bronchiol
howev
larger
doubleblind
placebocontrol
studi
children
age
month
hospit
first
second
episod
physiciandiagnos
rsv
bronchiol
random
placebo
montelukast
mgday
week
week
definit
studi
signific
differ
seen
montelukast
placebo
group
percentag
symptomfre
day
either
treatment
period
studi
suggest
class
compound
use
prevent
postbronchiol
respiratori
symptom
mani
mediat
cytokin
found
augment
viral
infect
futur
studi
determin
whether
inhibit
specif
compon
virusinduc
inflamm
proinflammatori
cytokin
eg
mediat
leukotrien
bradykinin
abl
provid
safe
effect
relief
virusinduc
wheez
asthma
efficaci
ltra
intermitt
viral
wheez
episod
preschool
children
studi
prevent
viral
induc
asthma
previa
trial
previa
random
doubleblind
placebocontrol
parallel
group
worldwid
trial
preschool
children
age
month
intermitt
asthmalik
symptom
day
symptomsweek
night
awakeningmonth
baselin
compar
montelukast
mg
daili
match
placebo
montelukast
better
placebo
reduc
rate
p
time
first
exacerbationcsw
episod
p
supplementari
ic
cours
p
howev
exacerbationscsw
episod
mild
requir
oc
montelukast
fail
reduc
oral
corticosteroid
cours
p
posthoc
analys
demonstr
effect
age
atop
statu
respons
therapi
recent
doubleblind
placebocontrol
clinic
trial
children
age
year
intermitt
asthma
random
receiv
treatment
montelukast
placebo
initi
parent
onset
upper
respira
nation
heart
lung
blood
institut
websit
wwwnhlbinihgov
american
academi
allergi
asthma
immunolog
websit
wwwaaaaiorg
childhood
asthma
research
educ
network
websit
wwwasthmacarenetorg
asthma
clinic
research
network
websit
wwwacrnorg
test
clinic
trial
includ
molecul
solubl
icam
capsidbind
agent
eg
pleconaril
either
hinder
hrv
bind
cellular
receptor
inhibit
uncoat
viru
releas
rna
insid
cell
inhibitor
hrv
proteas
clear
whether
antivir
agent
prevent
asthma
exacerb
given
first
sign
cold
viral
infect
import
caus
wheez
ill
children
age
progress
made
toward
understand
mechan
virus
caus
acut
wheez
perhap
even
importantli
sever
viral
infect
influenc
pathophysiolog
asthma
number
way
see
figur
mechan
establish
may
possibl
identifi
greater
certainti
children
greatest
risk
wheez
viral
infect
children
whose
virusinduc
wheez
prefac
asthma
would
repres
import
step
forward
prevent
therapi
could
focus
group
greatest
need
cours
rational
identifi
pathogen
mechan
virusinduc
wheez
identifi
target
novel
therapeut
strategi
standard
therapi
asthma
satisfactori
efficaci
low
respiratori
infect
case
system
corticosteroid
sideeffect
signific
given
close
relationship
viral
infect
wheez
ill
children
would
attract
appli
antivir
strategi
prevent
treatment
asthma
hrv
rsv
obviou
target
unfortun
attempt
develop
rsv
vaccin
far
unsuccess
vaccin
prevent
hrv
infect
seem
feasibl
larg
number
serotyp
altern
sever
type
antivir
agent
develop
sever
compound
activ
hrv
test
clinic
trial
potenti
therapeut
approach
respiratori
viral
infect
would
inhibit
proinflammatori
immun
respons
induc
viru
approach
prove
effect
system
administr
glucocorticoid
reduc
acut
airway
obstruct
risk
hospit
virusinduc
exacerb
asthma
remain
demonstr
whether
focus
inhibit
specif
compon
virusinduc
inflamm
proinflammatori
cytokin
eg
mediat
leukotrien
bradykinin
success
reduc
sever
viral
respiratori
infect
exacerb
asthma
evid
asthma
may
associ
defect
immun
respons
virus
allergen
also
could
lead
novel
therapeut
strategi
infanc
seem
time
immun
respons
rapidli
develop
process
appear
respons
environment
stimuli
perhap
dietari
factor
lifestyl
intrigu
children
expos
rich
microbi
environ
exposur
pet
farm
anim
less
like
develop
acut
chronic
wheez
suggest
environment
factor
posit
modifi
immun
develop
strengthen
antivir
respons
childhood
futur
goal
includ
develop
new
treatment
enhanc
supplement
antivir
respons
infanc
treat
acut
wheez
episod
perhap
reduc
risk
subsequ
asthma
